Full Text View
Tabular View
Study Results
Related Studies
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
This study has been completed.
Study NCT00324116   Information provided by Pfizer

First Received on May 8, 2006.   Last Updated on March 15, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Macular Degeneration
More general conditions related to this trial
Eye Diseases
Retinal Degeneration
Retinal Diseases
Interventions listed in this trial
pegaptanib sodium (Macugen)
Sponsors listed in this trial
Pfizer
ITEC GROUP 3


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services